-
014-5069-87
Drug Benefit Claim Reversal FormUsed by pharmacies for submitting claims or reversals014-2784-87
Drug Benefit Claim Submission FormUsed by pharmacies for submitting claims014-3975-87
Visudyne Therapy Registration/Funding EnrollmentApplication for reimbursement of cost due to use of Visudynecsr-21
Form 21 - Affidavit in Support of Application for Review of Parole Ineligibility (Criminal Code, s. 745.6(1) and Ontario Review of Parole Ineligibility Rules (Rule 50), Subrule 50.02(2))1. Affidavit in Support of Application for Review of Parole Ineligibility; 2. Affidavit of applicant setting out that the facts in the application are truecsr-20
Form 20 - Application for Review of Parole Ineligibility (Criminal Code, s. 745.6(1) and Ontario Review of Parole Ineligibility Rules, Rule 50.02(1))1. Application for Review of Parole Ineligibility; 2. Form for offenders to use when applying to the court to reduce their period of parole ineligibility4872
Supporting Information for a Maximum Ground Level Concentration Acceptability Request for Compounds with No Ministry Point of Impingement (POI) Limit Supplement to Application For Approval, EPA S.9This form is used when a contaminant with no Ministry POI Limit is identified as apart of an Emission Summary and Dispersion Modelling (ESDM) Report.csr-23-35
Form 23 - Pre-Hearing Conference Report for Crown Applications (Pursuant to Part XXIV) (Criminal Code, s. 625.1 and Criminal Proceedings Rules, Rule 35)1. Pre-hearing conference report for Crown Applications for Dangerous or Long-Term Offender designations; 2. Form for Crown and defence to complete in preparation for Dangerous and Long Term Offender hearings014-4846-87
Request for Aldurazyme®To facilitate prescribers making reimbursement claims for treatment of Hurler-Scheie and Hurler disease014-4908-87
Initial Request for Compassionate Review PolicyTo help physicians to submit requests for drug funding for their ODB-eligible patients under the Compassionate Review Policy.014-4777-87
Request for Zavesca® - Niemann Pick Type C (NPC)To facilitate prescribers making reimbursement claims for treatment of Niemann Pick Type C (NIPC).014-4717-87
Submission of Patient EvidenceTo provide patient advocacy groups with a template for written submissions to the ministry on a drug; the form is to make sure all the appropriate information is provided.014-2772-87
Special Authorization (Allergen)Used for obtaining authorization for allergen exact as an ODB benefit014-4906-87
Fabry Disease Enzyme Replacement Therapy (Agalsidase) AssessmentApplication form for drug therapy for Fabry disease014-4907-87
Fabry Disease Enzyme Replacement Therapy (Agalsidase) RenewalRenewal form dor drug therapy for Fabry disease014-4723-87
Submission of Patient Evidence Patient Advocacy Groups - Registration FormTo allow patient advocacy groups to register into the database so that they provide written submissions to the ministry on a drug; the form is to make sure all the appropriate information is provided.014-4551-87
Application and Consent for the Inherited Metabolic Diseases (IMD) ProgramFor physicians and patients to apply for the Inherited Metabolic Disorders (IMD) Program.014-5056-87
Information Available to Health Care Providers through the Digital Health Drug Repository“The Digital Health Drug Repository (DHDR) Reference Guide may be used by health care providers to understand the inclusions and limitations of the information available through the DHDR.”014-4940-87
Exceptional Access Program (EAP) Request OxyNEO (Oxycodone Hydrochloride Controlled Release) TabletsThe purpose of the e-Form is to assist physicians in the EAP drug request process by integrating all the rules/criteria into an interactive e-Form that will ensure all the necessary information is captured.014-4943-87
Exceptional Access Program (EAP) Request Lovenox (Enoxaparin Sodium) TherapyThe purpose of the e-Form is to assist physicians in the EAP drug request process by integrating all the rules/criteria into an interactive e-Form that will ensure all the necessary information is captured.
